Conolidine’s analgesic results stem from its conversation with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors during the central anxious method, conolidine modulates alternate molecular targets. A Science Advancements analyze identified that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. B... https://christopherf641fhl3.wikiadvocate.com/user